RELMADA THERAPEUTICS, INC.

Over the past 90 days, RELMADA THERAPEUTICS (RLMD) has reported zero cyber incidents, zero red-flag 8-K filings, and no officer departures or restatement events detected by our ingestion pipeline. This quiet period offers limited signal; a biotech company's risk profile depends heavily on longer historical patterns, equity dilution trajectory, and capital structure. The full $49 Report extends analysis to 12 months of SEC filings, applies our dilution risk score, maps financing history, and flags early-stage AI risk signals relevant to clinical-stage therapeutics. The full $49 Report adds comprehensive dilution analysis, detailed 8-K context, 12-month financing trends, and sector-specific risk signals that a 90-day snapshot cannot capture.